Only in Titles

Search results for: Urokinase

paperclip

Error loading info... Pleas try again later.
paperclip

#35037393   2022/01/17 To Up

Alpha-2-macroglobulin in hemostasis and thrombosis: an underestimated old double-edged sword.

A
Jeremy Lagrange, Thomas Lecompte, Tanja Knopp, Patrick Lacolley, Véronique Regnault

1763 related Products with: Alpha-2-macroglobulin in hemostasis and thrombosis: an underestimated old double-edged sword.

100ug Lyophilized100ug500 100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug100ug100ug100ug Lyophilized0.1 ml 100ul

Related Pathways

    No related Items
paperclip

#35035630   2022/01/12 To Up

Transcatheter aspiration of a thrombus and percutaneous transluminal coronary recanalization for ST-segment elevation myocardial infarction related to coronavirus disease 2019.

Although the novel coronavirus disease 2019 (COVID-19) causes severe viral pneumonia, it has also been reported, in some cases, to co-exist with ST-segment elevation myocardial infarction. Here, we describe the case of a patient with COVID-19 and coronary risk factors for hypertension, including smoking and obesity, who developed acute myocardial infarction due to primary coronary artery thrombosis and was treated with transcatheter thrombus aspiration and percutaneous transluminal coronary recanalization (PTCR) with intracoronary urokinase administration. A large volume of thrombus was collected and thrombolysis in myocardial infarction flow grade 3 was obtained after the procedures. PTCR with or without transcatheter thrombus aspiration may be a useful treatment option.
Eiko Sakai, Tatsuya Fujinami, Aya Yamaguchi, Kuniyoshi Sato, Yuta Taomoto, Takuya Adachi, Takashi Shibui, Akihiro Hata

2337 related Products with: Transcatheter aspiration of a thrombus and percutaneous transluminal coronary recanalization for ST-segment elevation myocardial infarction related to coronavirus disease 2019.

430 tests100 430 Tests / Kit1 mg600 Tests / Kit 6 ml Ready-to-use 5 g1 kit(96 Wells)0.1 mg100 100ug

Related Pathways

paperclip

#35028228   2021/12/10 To Up

Serpentine Thrombus in Right Atrium: A Tell-Tale Sign of Venous Thromboembolism.

Pulmonary embolism is linked with a remarkable rate of mortality, particularly when it is associated with hemodynamic instability, right atrial thrombus and related right ventricular dysfunction. In patients affected with pulmonary embolism, thrombolysis has been documented to be life-saving. The administration of thrombolytic agents ensures early resolution of the thrombus and prevents arrhythmia and cardiogenic shock. Streptokinase, urokinase and alteplase are among the three thrombolytic agents approved for the treatment of pulmonary embolism. In emergency situations, thrombectomy plays a crucial role.
Vidyashree Hulkoti, Sandeep Kamat, Sourya Acharya, Samarth Shukla, Sunil Kumar, Dhruv Talwar

2629 related Products with: Serpentine Thrombus in Right Atrium: A Tell-Tale Sign of Venous Thromboembolism.

2 Pieces/Box300 units2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box

Related Pathways

paperclip

#35026004   2022/01/13 To Up

Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock.

Microvesicles (MVs) have previously been shown to exert profibrinolytic capacity, which is increased in patients with septic shock (SS) with a favorable outcome. We therefore hypothesized that the plasmin generation capacity (PGC) could confer to MVs a protective effect supported by their capacity to lyse a thrombus, and we investigated the mechanisms involved. Using a MV-PGC kinetic assay, ELISA and flow cytometry, we found that granulocyte MVs (Gran-MVs) from SS patients display a heterogeneous PGC profile driven by the uPA (urokinase)/uPAR system. In vitro, these MVs lyse a thrombus according to their MV-PGC levels in a uPA/uPAR-dependent manner, as shown in a fluorescent clot lysis test and a lysis front retraction assay. Fibrinolytic activators conveyed by MVs contribute to approximately 30% of the plasma plasminogenolytic capacity of SS patients. In a murine model of SS, the injection of high PGC Gran-MVs significantly improved mouse survival and reduced the number of thrombi in vital organs. This was associated with a modification of the mouse coagulation and fibrinolysis properties toward a more fibrinolytic profile. Interestingly, mouse survival was not improved when soluble uPA was injected. Finally, using a multiplex array on plasma from SS patients, we found that neutrophil elastase correlates with the effect of high-PGC-capacity plasma and modulates the Gran-MV plasmin generation capacity by cleaving uPA-PAI-1 complexes. In conclusion, we show that high PGC level displayed by Gran-MVs reduce thrombus formation and improve survival conferring to Gran-MVs a protective role in a murine model of sepsis.
Sylvie Cointe, Loris Vallier, Pierre Esnault, Mathilde Dacos, Amandine Bonifay, Nicolas Macagno, Karim Harti Souab, Corinne Chareyre, Coralie Judicone, Diane Frankel, Stephane Robert, Sami Hraiech, Marie-Christine Alessi, Philippe Poncelet, Jacques Albanese, Françoise Dignat-George, Romaric Lacroix

2288 related Products with: Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock.

4 Membranes/Box2 Pieces/Box4 Membranes/Box2 Pieces/Box4 Arrays/Slide4 Arrays/Slide4 Membranes/Box2 Pieces/Box4 Membranes/Box2 Pieces/Box

Related Pathways

paperclip

#35019268   2022/01/12 To Up

Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers.

Thrombolytic (clot-busting) therapies with plasminogen activators (PAs) are first-line treatments against acute thrombosis and ischemic stroke. However, limitations such as narrow therapeutic windows, low success rates, and bleeding complications hinder their clinical use. Drug-loaded polyphenol-based nanoparticles (NPs) could address these shortfalls by delivering a more targeted and safer thrombolysis, coupled with advantages such as improved biocompatibility and higher stability in vivo. Herein, a template-mediated polyphenol-based supramolecular assembly strategy is used to prepare nanocarriers of thrombolytic drugs. A thrombin-dependent drug release mechanism is integrated using tannic acid (TA) to cross-link urokinase-type PA (uPA) and a thrombin-cleavable peptide on a sacrificial mesoporous silica template via noncovalent interactions. Following drug loading and template removal, the resulting NPs retain active uPA and demonstrate enhanced plasminogen activation in the presence of thrombin (1.14-fold; < 0.05). Additionally, they display lower association with macrophage (RAW 264.7) and monocytic (THP-1) cell lines (43 and 7% reduction, respectively), reduced hepatic accumulation, and delayed blood clearance in vivo (90% clearance at 60 min vs 5 min) compared with the template-containing NPs. Our thrombin-responsive, polyphenol-based NPs represent a promising platform for advanced drug delivery applications, with potential to improve thrombolytic therapies.
Haitao Yu, Jason S Palazzolo, Jiajing Zhou, Yingjie Hu, Be'eri Niego, Shuaijun Pan, Yi Ju, Ting-Yi Wang, Zhixing Lin, Christoph E Hagemeyer, Frank Caruso

2967 related Products with: Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers.

500 tests100 assays100 assays100 assays100tests100 assays100 assays100 assays100 assays

Related Pathways

paperclip

#35018646   2022/01/12 To Up

A minimally invasive strategy to evacuate hematoma by synergy of an improved ultrasonic horn with urokinase: an in-vitro study.

In this study, Ultrasound Needle-an improved minimally invasive ultrasonic horn device was used to explore its potential of synergizing with urokinase in enhancing clots lysis in an in-vitro intracranial hematoma model.
Junhui Tang, Jiawei Tang, Qiong Zhu, Yiyi Liao, Luhua Bai, Tingting Luo, Shuang Feng, Zheng Liu

1327 related Products with: A minimally invasive strategy to evacuate hematoma by synergy of an improved ultrasonic horn with urokinase: an in-vitro study.

1 kit(96 Wells)1 kit(96 Wells)1 module1mg1 ml1 module1 kit(96 Wells)1 mg200 ug1 module

Related Pathways

paperclip

#35008762   2021/12/29 To Up

The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.

Angiogenesis is a process associated with the migration and proliferation of endothelial cells (EC) to form new blood vessels. It is involved in various physiological and pathophysiological conditions and is controlled by a wide range of proangiogenic and antiangiogenic molecules. The plasminogen activator-plasmin system plays a major role in the extracellular matrix remodeling process necessary for angiogenesis. Urokinase/tissue-type plasminogen activators (uPA/tPA) convert plasminogen into the active enzyme plasmin, which in turn activates matrix metalloproteinases and degrades the extracellular matrix releasing growth factors and proangiogenic molecules such as the vascular endothelial growth factor (VEGF-A). The plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of uPA and tPA, thereby an inhibitor of pericellular proteolysis and intravascular fibrinolysis, respectively. Paradoxically, PAI-1, which is expressed by EC during angiogenesis, is elevated in several cancers and is found to promote angiogenesis by regulating plasmin-mediated proteolysis and by promoting cellular migration through vitronectin. The urokinase-type plasminogen activator receptor (uPAR) also induces EC cellular migration during angiogenesis via interacting with signaling partners. Understanding the molecular functions of the plasminogen activator plasmin system and targeting angiogenesis via blocking serine proteases or their interactions with other molecules is one of the major therapeutic strategies scientists have been attracted to in controlling tumor growth and other pathological conditions characterized by neovascularization.
Asmaa Anwar Ismail, Baraah Tariq Shaker, Khalid Bajou

2958 related Products with: The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.

96 Tests/kit200 200 1mg100.00 ug200 0.1mg1 kit(96 Wells)4 Arrays/Slide10mg100.00 ug48 samples

Related Pathways

paperclip

#35008467   2021/12/21 To Up

A Comparison between Enrichment Optimization Algorithm (EOA)-Based and Docking-Based Virtual Screening.

Virtual screening (VS) is a well-established method in the initial stages of many drug and material design projects. VS is typically performed using structure-based approaches such as molecular docking, or various ligand-based approaches. Most docking tools were designed to be as global as possible, and consequently only require knowledge on the 3D structure of the biotarget. In contrast, many ligand-based approaches (e.g., 3D-QSAR and pharmacophore) require prior development of project-specific predictive models. Depending on the type of model (e.g., classification or regression), predictive ability is typically evaluated using metrics of performance on either the training set (e.g.,QCV2) or the test set (e.g., specificity, selectivity or QF1/F2/F32). However, none of these metrics were developed with VS in mind, and consequently, their ability to reliably assess the performances of a model in the context of VS is at best limited. With this in mind we have recently reported the development of the enrichment optimization algorithm (EOA). EOA derives QSAR models in the form of multiple linear regression (MLR) equations for VS by optimizing an enrichment-based metric in the space of the descriptors. Here we present an improved version of the algorithm which better handles active compounds and which also takes into account information on inactive (either known inactive or decoy) compounds. We compared the improved EOA in small-scale VS experiments with three common docking tools, namely, Glide-SP, GOLD and AutoDock Vina, employing five molecular targets (acetylcholinesterase, human immunodeficiency virus type 1 protease, MAP kinase p38 alpha, urokinase-type plasminogen activator, and trypsin I). We found that EOA consistently outperformed all docking tools in terms of the area under the ROC curve (AUC) and EF metrics that measured the overall and initial success of the VS process, respectively. This was the case when the docking metrics were calculated based on a consensus approach and when they were calculated based on two different sets of single crystal structures. Finally, we propose that EOA could be combined with molecular docking to derive target-specific scoring functions.
Jacob Spiegel, Hanoch Senderowitz

1590 related Products with: A Comparison between Enrichment Optimization Algorithm (EOA)-Based and Docking-Based Virtual Screening.

100testsOne 96-Well Microplate Ki500 tests100ug100 assays

Related Pathways

paperclip

#35005315   2021/10/30 To Up

Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.

Severe, nonresponsive, primary focal segmental glomerular sclerosis (FSGS) can progress to end-stage kidney disease (ESKD) in <5 years. Soluble urokinase-type plasminogen activator receptor (suPAR) may contribute to podocyte effacement by activating podocyte β3 integrin. It has been reported as a potential permeability factor and biomarker for primary FSGS. Rituximab was found to have efficacy in case reports and small series. Whether rituximab is efficacious in patients with treatment-resistant FSGS in the context of high suPAR levels and evidence of podocyte B3 integrin activation remains unknown.
Michelle A Hladunewich, Dan Cattran, Sanjeev M Sethi, Salim S Hayek, Jing Li, Changli Wei, Sarah I Mullin, Heather N Reich, Jochen Reiser, Fernando C Fervenza

1046 related Products with: Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.

100.00 ug50 ug100.00 ug0.1mg50ul96T1 mg96 Tests/kit100.00 ug96tests1mg

Related Pathways